Preoperative systemic chemotherapy and pathologic assessment of response

Pathology and Oncology Research

Volumn 14, Issue 2, 2008, Pages 169-171

  Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Preoperative systemic therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CARCINOMA IN SITU; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; INTERMETHOD COMPARISON; INVASIVE CARCINOMA; MINIMAL RESIDUAL DISEASE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58549117098     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-008-9070-8     Document Type: Article

References (18)

1. P Rastogi SJ Anderson HD Bear CE Geyer MS Kahlenberg A Robidoux RG Margolese JL Hoehn VG Vogel SR Dakhil D Tamkus KM King ER Pajon MJ Wright J Robert S Paik EP Mamounas N Wolmark 2008 Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 J Clin Oncol 26 778 785
2. JC Boughey F Peintinger F Meric-Bernstam AC Perry KK Hunt GV Babiera SE Singletary I Bedrosian A Lucci AU Buzdar L Pusztai HM Kuerer 2006 Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer Ann Surg 244 464 470
3. G Bonadonna U Veronesi C Brambilla 1990 Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more J Natl Cancer Inst 82 1539 1545
4. D Mauri N Pavlidis JP Ioannidis 2005 Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis J Natl Cancer Inst 97 188 194
5. AM Chen F Meric-Bernstam KK Hunt 2004 Breast-conserving therapy after neoadjuvant chemotherapy: The M. D. Anderson Cancer Center experience J Clin Oncol 22 2303 2312
6. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685
7. IC Smith SD Heys AW Hutcheon ID Miller S Payne FJ Gilbert AK Ah-See O Eremin LG Walker TK Sarkar 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456 1466
8. G von Minckwitz S Kummel P Vogel 2008 Neoadjuvant vinorelbine- capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial J Natl Cancer Inst 100 542 551
9. AC Wolff D Berry LA Carey M Colleoni M Dowsett M Ellis G Je D Mankoff S Paik L Pusztai ML Smith JA Zujewski 2008 Research issues affecting preoperative systemic therapy for operable breast cancer J Clin Oncol 26 806 813
10. LA Carey R Metzger EC Dees 2005 American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome J Natl Cancer Inst 97 1137 1142
11. HM Kuerer LA Newman TL Smith 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469
12. R Rouzier JM Extra J Klijanienko 2002 Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes J Clin Oncol 20 1304 1310
13. C Mazouni F Peintinger SW Kau F Andre AM Gonzalez-Angulo WF Symmans F Meric-Bernstam V Valero GN Hortobagyi L Pusztai 2007 Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome J Clin Oncol 25 2650 2655
14. WF Symmans F Peintinger C Hatzis R Rajan HM Kuerer V Valero L Assad A Poniecka TJ Hennessy MC Green AU Buzdar SE Singletary GN Hortobagyi L Pusztai 2007 Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 4414 4422
15. FJ Esteva GN Hortobagyi 2008 Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer? J Natl Cancer Inst 100 521 523
16. R Rouzier L Pusztai S Delaloge AM Gonzalez-Angulo F Andre KR Hess AU Buzdar JR Garbay M Spielmann MC Mathieu WF Symmans P Wagner D Atallah V Valero DA Berry GN Hortobagyi 2005 Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer J Clin Oncol 23 8331 8339
17. F Andre C Mazouni C Liedtke SW Kau D Frye M Green AM Gonzalez-Angulo WF Symmans GN Hortobagyi L Pusztai 2008 HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer Breast Cancer Res Treat 108 183 190
18. L Gianni M Zambetti K Clark J Baker M Cronin J Wu G Mariani J Rodriguez M Carcangiu D Watson P Valagussa R Rouzier WF Symmans JS Ross GN Hortobagyi L Pusztai S Shak 2005 Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer J Clin Oncol 23 7265 7277